Drug Database
Back to search

Poland· PL-100426948

Lamivudine Aurovitas

A lamivudine product containing lamivudinum, registered in Poland by Aurovitas Pharma Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.

ATC J05AF05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLamivudine AurovitasATCJ05AF05REGISTER NO.PL-100426948PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lamivudinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lamivudine is registered in 17 of 19 countries.

Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search lamivudine products by name

Lamivudine · ATC J05AF05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lamivudine costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lamivudine · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$7.71
  • IT Italy$6.75
  • FR France$2.42
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Lamivudinum
Manufacturer
Aurovitas Pharma Polska Sp. z o.o.
Country
Poland (PL)
ATC code
J05AF05
ATC class
Lamivudine
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991464127
  • gtin
    05909991464134

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

207 interactions on record for lamivudine.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lamivudine against other medicinesHow interaction checks work

Lamivudine · interactions on record

207 records

  • 6 severe
  • 36 moderate
  • 165 info

Most severe, free to view

  • BexaroteneL01XF03severe
  • BexarotenL01XX25severe
  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lamivudine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

  • Austria · Lamivudin Sandoz
  • Cyprus · Lamivudine Normon
  • Germany · Lamivudin Aurobindo, Lamivudin Mylan
  • Spain · Lamivudina Accord, Lamivudina Aurovitas
  • France · Lamivudine Arrow, Lamivudine Sandoz
  • United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
  • Iceland · Epivir, Lamivudine Teva
  • Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
  • Liechtenstein · Epivir, Lamivudine Teva
  • Netherlands · Lamivudine Accord, Lamivudine Aurobindo
  • Norway · Epivir, Lamivudine Teva
  • Portugal · Lamivudina Aurobindo, Lamivudina Farmoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/30357d61-9853-4cd7-bb6b-7dd26617503d
GET /v1/drugs/30357d61-9853-4cd7-bb6b-7dd26617503d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05909991464127 ¦ Rp ¦ 141724\n28 tabl.\n05909991464134 ¦ Rp ¦ 141725\n84 tabl.",
  "substance": "Lamivudinum 100 mg",
  "common_name": "Lamivudinum",
  "pl_product_id": "100426948",
  "pozwolenie_nr": "26608",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about lamivudine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console